

**Abstract Submission No.: A-0458****Addressing the Decline in Peritoneal Dialysis Prevalence: The 2023 Initiatives  
of the Peritoneal Dialysis Reimbursement Program in Taiwan**

**Yen-Hsuan Tai**<sup>1</sup>, Yang Ho<sup>1</sup>, Mu-Chi Chung<sup>2</sup>, Ben-Chung Cheng<sup>3</sup>, Chih-Yu Yang<sup>1</sup>, Chih-Ching Lin<sup>1</sup>,  
Yung-Ho Hsu<sup>4</sup>, Kuan-Yu Hung<sup>4</sup>, Der-Cherng Tarng<sup>1</sup>, Peritoneal Dialysis Working Committee<sup>5</sup>

<sup>1</sup>Department of Internal Medicine-Nephrology, Taipei Veterans General Hospital, Taipei, Taiwan

<sup>2</sup>Department of Internal Medicine-Nephrology, Taichung Veterans General Hospital, Taichung, Taiwan

<sup>3</sup>Department of Internal Medicine-Nephrology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung,  
Taiwan

<sup>4</sup>Department of Internal Medicine-Nephrology, Taipei Medical University Hospital, Taipei, Taiwan

<sup>5</sup>Department of Peritoneal Dialysis Working Committee, Taiwan Society of Nephrology, Taipei, Taiwan

**Objectives :** The global utilization rate of peritoneal dialysis (PD) varies significantly, reflecting differences in clinicians' discretion, healthcare systems, and government policies. The 5-year cumulative survival rate (2011-2015) for PD patients in Taiwan was 54.9%, ranking second only to South Korea (71.5% in 2013) and the United States (57.8% in 2014). Moreover, the incidence of PD peritonitis in Taiwan has consistently decreased over the years (2016-2020). However, despite the exceptional quality of PD care in Taiwan, the incidence of PD as a dialysis modality declined from 14.2% in 2007 to 9.7% in 2020, and its prevalence decreased from 9.6% in 2011 to 7.8% in 2020, which was lower than those in Hong Kong (67.3%), Norway (23.5%), Singapore (13%), and the United States (12%).

**Methods :** The declining PD utilization rate in Taiwan might be attributed to insufficient information for patients to choose the most suitable renal replacement therapy (RRT) modality. Enforcing a policy to encourage PD therapy among specific patient populations is crucial, given its benefits for proactive patients and reduced hospital visits. To address these trends, Taiwan's National Health Insurance Administration launched a reimbursement program in July 2023, guided by the expertise of the Peritoneal Dialysis Working Committee of the Taiwan Society of Nephrology.

**Results :** This initiative encourages the establishment of new PD units, education for new staff, and an integrative care approach provided by medical centers and their collaborative community clinics. Additionally, this program encourages comprehensive shared decision-making on RRT modality choice and reimburses telemedicine video consultations as well as remote patient management. Table 1 summarizes the items included in this initiative.

**Conclusions :** This initiative is still ongoing and will continue at least until the end of 2024. These efforts are anticipated to further optimize PD care in Taiwan, thereby enhancing the quality of life and clinical outcomes of patients.

**Table 1.** Summary of the 2023 Initiatives of the Peritoneal Dialysis (PD) Reimbursement Program in Taiwan

<b>Goals</b>	
1. Increase the incidence of PD as a dialysis modality to over 10% in 2024, up from 9.7%	
2. Increase the prevalence of PD as a dialysis modality to exceed 8% in 2024, up from 7.8%	
<b>Reimbursement Items</b>	
Increase the utilization rate of PD therapy	1. Reimburse start-up expenses for establishing a new PD unit 2. Reimburse PD units for new PD patients who have remained stable on PD therapy for more than six months 3. Reward PD units based on their unit-annual growth in the number of PD patients
Encourage shared decision-making (SDM)	Reimburse SDM for renal replacement therapy (RRT) modality choices in patients with CKD stage 5, as well as for those who have initiated RRT within the past 2 years
Enhance the quality of PD care	Reward PD units for achieving high-standard quality indices on a PD unit-scale basis, which include limited use of high-glucose dialysate, reductions in hyponatremia, hypokalemia, and the cardiothoracic ratio, preservation of residual renal function, and reductions in peritonitis incidence and hospitalization rates
Reimburse remote patient management (RPM)	1. Reimburse telemedicine video consultations for PD patients 2. Reimburse remote management for PD and automated PD patients
<b>Anticipated Achievements</b>	
1. Empower all ESKD patients to make informed and objective choices regarding their RRT modalities, ensuring their complete consent and understanding	
2. Increase the nationwide prevalence of PD patients	
3. Improve the quality of PD care and the survival rates of PD patients	

**Acknowledgements:** The authors extend hearty appreciation to all the members of the 2023-2026 Peritoneal Dialysis Working Committee of the Taiwan Society of Nephrology, listed in alphabetical order by their last names: Jo-Yen Chao, Jui-Ting Chang, Ming-Yang Chang, Fu-An Chen, Hsi-Hsien Chen, Ben-Chung Cheng, Yi-Wen Chiu, Mu-Chi Chung, Yang Ho, Jyh-Tong Hsieh, Chih-Yang Hsu, Yung-Ho Hsu, Kuan-Yu Hung, Ming-Yu Lai, David Law, Meng-Hung Lee, Chia-Te Liao, Hsin-Tai Lin, Chi-Feng Pan, Chiao-Yin Sun, Po-Yu Tsai, Kuo-Hsien Tseng, Chih-Hsien Wang, Han-En Wang, I-Kuan Wang, Chia-Lin Wu, Tai-Te Wu, Chih-Yu Yang, Zi-Hong You.